Bedell Frazier Investment Counselling’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-34,430	Closed	-$3.34M	–	49
2018 Q3	$3.34M	Sell	34,430 -495	-1%	-$49.4K	0.92%	40
2018 Q2	$3.29M	Sell	34,925 -655	-2%	-$57.4K	0.96%	38
2018 Q1	$2.88M	Buy	+35,580	New	+$3.05M	1.02%	35

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bedell Frazier Investment Counselling's BMRN Position: Q4 2018 in Review

Bedell Frazier Investment Counselling sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 34,430 shares — an estimated $3.34M sold.

Bedell Frazier Investment Counselling first reported a position in BMRN in Q1 2018 and held it in 3 quarters. The position peaked at $3.34M in Q3 2018. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

Bedell Frazier Investment Counselling reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Bedell Frazier Investment Counselling sold 34,430 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $3.34M.
Bedell Frazier Investment Counselling first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Bedell Frazier Investment Counselling's BioMarin Pharmaceuticals position peaked at $3.34M in Q3 2018.
473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Bedell Frazier Investment Counselling's 13F filing for Q4 2018, filed 14 Feb 2019.